BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Stem Cells

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

BrightPath Bio

More Like This

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

PR Newswire associated0

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

PR Newswire associated0

Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

CRISPR-Ready ioGlutamatergic Neurons (Graphic: Business Wire)

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options